BioSpace News Archive

The U.S. Food and Drug Administration today cleared the first contact lens to incorporate an additive that automatically darkens the lens when exposed to bright light

Vizient, Inc. applauds the Drug Enforcement Administration (DEA) for working with health care industry stakeholders to take steps to alleviate certain drug shortages facing the nation’s acute care providers.

JPT Peptide Technologies (JPT) announces the launch of The Human Proteome Peptide Catalog, the first and most comprehensive online resource for validated reference peptides in mass-spectrometry based proteomics.

Pfizer Inc. today announced that the independent Data Monitoring Committee for the Phase 3 ATLAS trial evaluating INLYTA® (axitinib) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy recommended stopping the trial at a planned interim analysis due to futility.

Arizona’s bioscience sector is adding jobs at a rate outpacing the biosciences nationally and the state’s overall private sector, while Arizona’s public universities are seeing increases in bioscience research funding, expenditures and tech transfer, a new report shows.

Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to bring much disruption to the PsA market

First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.

The relationship between pharmaceutical companies and patient advocacy groups is long and deep and involves millions of dollars in donations, a new report reveals.

Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.

Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling. It will seek approval for a version of Illumina’s TruSight Tumor 170 as a companion diagnostic for Loxo Oncology’s larotrectinib and LOXO-292.